Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/44208
Title: Current pharmacotherapy of overactive bladder
Authors: KREYDIN, Evgenyi I.GOMES, Cristiano M.CRUZ, Francisco
Citation: INTERNATIONAL BRAZ J UROL, v.47, n.6, p.1091-1107, 2021
Abstract: Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia


Files in This Item:
File Description SizeFormat 
art_KREYDIN_Current_pharmacotherapy_of_overactive_bladder_2021.PDFpublishedVersion (English)280.52 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.